Patienterne skal overvåges tæt for faldende trombocyttal og skal behandles medicinsk for at undgå blødning efter ophør af behandling med romiplostim.
Patients should be closely monitored for a decrease in platelet count and medically managed to avoid bleeding upon discontinuation of treatment with romiplostim.